Epidemiological studies and clinical trials involving optical devices for myopia will be the focus of a new three-year agreement between the Brien Holden Vision Institute (BHVI) and a leading Chinese eye hospital network.
The Sydney-based institute has penned a new deal with AIER Eye Hospital Group to continue collaborative work on key projects within the burgeoning field of myopia management.
The two entities have been working together since 2015. AIER has established more than 500 specialised hospitals globally, encompassing 30 provinces across China. It is also the first Chinese IPO-listed medical institution.
“[This] signing marks a significant step forward in our collaboration with AIER,” said Professor Padmaja Sankaridurg, program leader of myopia at BHVI.
“AIER and BHVI are deeply committed to this ongoing partnership as we work together on key aspects of myopia management, including conducting trials and disseminating information via scientific journals for the benefit of the broader population.
“Rebecca Weng and I have been working closely with Dr Weizhang Lan and Dr Yang from AIER and we are pleased to be able to continue and further the epidemiological studies and clinical trials involving optical devices with scientists that we admire greatly.”
Myopia currently affects more than a quarter of the world’s population, with the numbers highest across East Asia.
More reading:
BHVI reaches multi-year deal with Optometry Giving Sight USA
German manufacturer licenses BHVI algorithms for new device
BHVI myopia education program available anytime, anywhere
